115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
那不勒斯预后评分与不可手术食管鳞状细胞癌患者接受放化疗联合免疫治疗生存率的相关性
Authors Wei X, Guo D , Cai Y, Li Y, Wang X, Zhang B, Li J , Hao F
Received 10 August 2025
Accepted for publication 17 December 2025
Published 8 January 2026 Volume 2026:19 559722
DOI https://doi.org/10.2147/JIR.S559722
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Dr Felix Marsh-Wakefield
Xinyue Wei,* Dong Guo,* Yuanyuan Cai, Yang Li, Xiaoxiao Wang, Bingyi Zhang, Jianwen Li, Furong Hao
Department of Radiation Oncology, Weifang People’s Hospital, Shandong Second Medical University, Weifang City, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jianwen Li, Department of Radiation Oncology, Weifang People’s Hospital, Shandong Second Medical University, Weifang City, 261000, People’s Republic of China, Email ljwwf112@163.com Furong Hao, Department of Radiation Oncology, Weifang People’s Hospital, Shandong Second Medical University, Weifang City, 261000, People’s Republic of China, Email hkc515@163.com
Objective: This study aimed to determine whether the Naples Prognostic Score (NPS) is an independent predictor of overall survival (OS) and progression-free survival (PFS) in patients with unresectable esophageal squamous cell carcinoma (ESCC) undergoing chemoradiotherapy combined with immunotherapy.
Materials and Methods: We analyzed 139 patients with inoperable ESCC undergoing chemoradiotherapy combined with immunotherapy between January 2020 and November 2024. We systematically evaluated the associations between NPS categories and clinical features across these cohorts. Kaplan-Meier analysis was employed to generate survival curves stratified by NPS. Univariate and multivariate Cox models assessed NPS as an independent predictor of OS and PFS for risk stratification.
Results: Stratification analysis based on the NPS revealed distinct survival outcomes: the median OS was 23 months for Group 0, 17.5 months for Group 1, and 11 months for Group 2. The corresponding PFS durations were 19.5 months (Group 0), 15 months (Group 1), and 9 months (Group 2), respectively. The prognostic value of NPS was confirmed by receiver operating characteristic (ROC) curve analysis, which yielded an area under the curve (AUC) of 0.701 (P < 0.05). Importantly, multivariate Cox regression analysis established NPS as an independent prognostic factor for both OS (HR: 2.404; 95% CI: 1.411– 4.095; P < 0.01) and PFS (HR: 2.203; 95% CI: 1.321– 3.674; P = 0.02). These results highlight the clinical significance of NPS in prognostic assessment and treatment strategy formulation for patients with inoperable ESCC.
Conclusion: The NPS has been demonstrated to be a reliable prognostic tool in unresectable ESCC. It provides a practical framework for baseline risk stratification at diagnosis to identify high-risk patients who may benefit from intensified nutritional support, closer surveillance, or enrollment in novel immunotherapy trials, thereby guiding personalized treatment and optimizing resource use.
Keywords: naples prognostic score, predictive values, inoperable ESCC, chemoradiotherapy, immunotherapy
Department of Radiation Oncology, Weifang People’s Hospital, Shandong Second Medical University, Weifang City, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jianwen Li, Department of Radiation Oncology, Weifang People’s Hospital, Shandong Second Medical University, Weifang City, 261000, People’s Republic of China, Email ljwwf112@163.com Furong Hao, Department of Radiation Oncology, Weifang People’s Hospital, Shandong Second Medical University, Weifang City, 261000, People’s Republic of China, Email hkc515@163.com
Objective: This study aimed to determine whether the Naples Prognostic Score (NPS) is an independent predictor of overall survival (OS) and progression-free survival (PFS) in patients with unresectable esophageal squamous cell carcinoma (ESCC) undergoing chemoradiotherapy combined with immunotherapy.
Materials and Methods: We analyzed 139 patients with inoperable ESCC undergoing chemoradiotherapy combined with immunotherapy between January 2020 and November 2024. We systematically evaluated the associations between NPS categories and clinical features across these cohorts. Kaplan-Meier analysis was employed to generate survival curves stratified by NPS. Univariate and multivariate Cox models assessed NPS as an independent predictor of OS and PFS for risk stratification.
Results: Stratification analysis based on the NPS revealed distinct survival outcomes: the median OS was 23 months for Group 0, 17.5 months for Group 1, and 11 months for Group 2. The corresponding PFS durations were 19.5 months (Group 0), 15 months (Group 1), and 9 months (Group 2), respectively. The prognostic value of NPS was confirmed by receiver operating characteristic (ROC) curve analysis, which yielded an area under the curve (AUC) of 0.701 (P < 0.05). Importantly, multivariate Cox regression analysis established NPS as an independent prognostic factor for both OS (HR: 2.404; 95% CI: 1.411– 4.095; P < 0.01) and PFS (HR: 2.203; 95% CI: 1.321– 3.674; P = 0.02). These results highlight the clinical significance of NPS in prognostic assessment and treatment strategy formulation for patients with inoperable ESCC.
Conclusion: The NPS has been demonstrated to be a reliable prognostic tool in unresectable ESCC. It provides a practical framework for baseline risk stratification at diagnosis to identify high-risk patients who may benefit from intensified nutritional support, closer surveillance, or enrollment in novel immunotherapy trials, thereby guiding personalized treatment and optimizing resource use.
Keywords: naples prognostic score, predictive values, inoperable ESCC, chemoradiotherapy, immunotherapy